BCL2 and B-cell non-Hodgkin lymphoma: The combination of volasertib, another PLK1 inhibitor, and ABT199 (inhibitor of BCL2) has recently been shown to be synergistic in several models of double-hit lymphoma (DHL), an aggressive subgroup of B cell lymphoma, both in vitro and in vivo, where the eradication of tumors in validated models of DHL was observed [77].